Ahmed Sallam
Concepts (386)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vitrectomy | 31 | 2024 | 59 | 9.830 |
Why?
| Visual Acuity | 40 | 2025 | 141 | 9.530 |
Why?
| Macular Edema | 18 | 2024 | 28 | 8.560 |
Why?
| Phacoemulsification | 18 | 2025 | 35 | 8.250 |
Why?
| Cataract | 14 | 2024 | 43 | 7.480 |
Why?
| Cataract Extraction | 15 | 2024 | 31 | 6.430 |
Why?
| Intraoperative Complications | 17 | 2025 | 113 | 6.430 |
Why?
| Retinal Detachment | 15 | 2024 | 25 | 5.760 |
Why?
| Tomography, Optical Coherence | 20 | 2024 | 104 | 5.080 |
Why?
| Diabetic Retinopathy | 10 | 2024 | 39 | 4.800 |
Why?
| Uveitis | 12 | 2024 | 20 | 4.070 |
Why?
| Postoperative Complications | 18 | 2024 | 1018 | 4.000 |
Why?
| Ophthalmology | 8 | 2023 | 32 | 3.850 |
Why?
| Glaucoma | 8 | 2024 | 32 | 3.620 |
Why?
| Glucocorticoids | 16 | 2024 | 229 | 3.420 |
Why?
| Endophthalmitis | 11 | 2023 | 24 | 3.340 |
Why?
| Epiretinal Membrane | 5 | 2024 | 10 | 3.320 |
Why?
| Retrospective Studies | 55 | 2025 | 6123 | 3.060 |
Why?
| Eye Infections, Bacterial | 8 | 2024 | 29 | 2.890 |
Why?
| Dexamethasone | 9 | 2023 | 424 | 2.740 |
Why?
| Lens Implantation, Intraocular | 10 | 2025 | 24 | 2.620 |
Why?
| Humans | 130 | 2025 | 49898 | 2.560 |
Why?
| Drug Implants | 9 | 2023 | 35 | 2.510 |
Why?
| Triticum | 4 | 2023 | 7 | 2.480 |
Why?
| Comprehension | 6 | 2024 | 113 | 2.460 |
Why?
| Fluorescein Angiography | 7 | 2024 | 33 | 2.270 |
Why?
| Syphilis | 5 | 2024 | 27 | 2.260 |
Why?
| Hordeum | 3 | 2022 | 5 | 2.130 |
Why?
| Vitreoretinal Surgery | 5 | 2024 | 8 | 2.120 |
Why?
| Intraocular Pressure | 10 | 2024 | 54 | 2.040 |
Why?
| Diabetes Mellitus | 4 | 2022 | 279 | 2.020 |
Why?
| Eye Infections, Fungal | 6 | 2021 | 19 | 1.940 |
Why?
| Retinal Vessels | 3 | 2024 | 14 | 1.930 |
Why?
| Retinal Vein Occlusion | 6 | 2023 | 14 | 1.920 |
Why?
| Papilledema | 4 | 2022 | 27 | 1.890 |
Why?
| Retinitis Pigmentosa | 2 | 2024 | 8 | 1.810 |
Why?
| Aged | 43 | 2025 | 9447 | 1.780 |
Why?
| Middle Aged | 46 | 2025 | 12285 | 1.730 |
Why?
| Aged, 80 and over | 26 | 2025 | 3136 | 1.650 |
Why?
| Pseudophakia | 6 | 2024 | 12 | 1.620 |
Why?
| Male | 63 | 2025 | 25437 | 1.610 |
Why?
| Fluorocarbons | 3 | 2023 | 49 | 1.500 |
Why?
| Angiogenesis Inhibitors | 7 | 2022 | 182 | 1.480 |
Why?
| Fibrin | 2 | 2023 | 10 | 1.450 |
Why?
| Female | 60 | 2025 | 26560 | 1.440 |
Why?
| Retinal Diseases | 7 | 2021 | 50 | 1.440 |
Why?
| Intravitreal Injections | 15 | 2023 | 33 | 1.430 |
Why?
| Paracentesis | 2 | 2023 | 13 | 1.430 |
Why?
| Databases, Factual | 10 | 2024 | 660 | 1.390 |
Why?
| Sclera | 2 | 2024 | 5 | 1.380 |
Why?
| Tissue Plasminogen Activator | 2 | 2023 | 110 | 1.340 |
Why?
| Macular Degeneration | 4 | 2024 | 27 | 1.300 |
Why?
| Lenses, Intraocular | 2 | 2022 | 7 | 1.280 |
Why?
| Retinal Perforations | 4 | 2023 | 7 | 1.210 |
Why?
| Choroid | 5 | 2024 | 14 | 1.190 |
Why?
| Retina | 7 | 2024 | 62 | 1.170 |
Why?
| Fractals | 2 | 2024 | 8 | 1.170 |
Why?
| Internet | 3 | 2024 | 261 | 1.140 |
Why?
| Iris Diseases | 3 | 2020 | 4 | 1.140 |
Why?
| Wet Macular Degeneration | 3 | 2022 | 6 | 1.130 |
Why?
| Lens, Crystalline | 2 | 2024 | 20 | 1.130 |
Why?
| Adult | 31 | 2024 | 13346 | 1.130 |
Why?
| Candidiasis | 3 | 2021 | 114 | 1.090 |
Why?
| Follow-Up Studies | 13 | 2024 | 2175 | 1.080 |
Why?
| Eye Injuries | 4 | 2024 | 25 | 1.060 |
Why?
| Societies, Medical | 3 | 2019 | 177 | 1.050 |
Why?
| Pilocarpine | 1 | 2024 | 25 | 0.960 |
Why?
| Retinitis | 2 | 2022 | 5 | 0.960 |
Why?
| Lens Subluxation | 1 | 2024 | 2 | 0.950 |
Why?
| Endotamponade | 4 | 2018 | 8 | 0.940 |
Why?
| Lighting | 1 | 2024 | 5 | 0.920 |
Why?
| Ciliary Body | 1 | 2024 | 3 | 0.920 |
Why?
| Anterior Chamber | 1 | 2023 | 6 | 0.910 |
Why?
| Laser Coagulation | 1 | 2024 | 26 | 0.900 |
Why?
| Ocular Hypertension | 2 | 2016 | 6 | 0.890 |
Why?
| Triamcinolone Acetonide | 5 | 2011 | 15 | 0.890 |
Why?
| Panuveitis | 2 | 2021 | 6 | 0.890 |
Why?
| Anesthesia, General | 3 | 2024 | 90 | 0.890 |
Why?
| Germination | 1 | 2023 | 5 | 0.860 |
Why?
| Endoscopy | 1 | 2024 | 118 | 0.850 |
Why?
| Treatment Outcome | 16 | 2024 | 5176 | 0.840 |
Why?
| Occlusive Dressings | 1 | 2022 | 6 | 0.840 |
Why?
| State Medicine | 5 | 2023 | 14 | 0.820 |
Why?
| Artificial Intelligence | 1 | 2023 | 82 | 0.820 |
Why?
| HIV Seropositivity | 1 | 2022 | 27 | 0.810 |
Why?
| Rift Valley Fever | 1 | 2022 | 1 | 0.810 |
Why?
| Reproducibility of Results | 8 | 2024 | 1182 | 0.810 |
Why?
| Antihypertensive Agents | 2 | 2016 | 124 | 0.810 |
Why?
| Optic Neuropathy, Ischemic | 1 | 2022 | 8 | 0.800 |
Why?
| Eye Foreign Bodies | 1 | 2022 | 6 | 0.790 |
Why?
| Enbucrilate | 1 | 2021 | 6 | 0.790 |
Why?
| Tissue Adhesives | 1 | 2021 | 13 | 0.790 |
Why?
| Incidence | 12 | 2024 | 986 | 0.780 |
Why?
| Stress, Physiological | 2 | 2019 | 173 | 0.760 |
Why?
| Child | 17 | 2024 | 6844 | 0.750 |
Why?
| Varicose Veins | 2 | 2019 | 19 | 0.750 |
Why?
| Droughts | 4 | 2023 | 9 | 0.750 |
Why?
| Candida | 4 | 2020 | 60 | 0.730 |
Why?
| Choroiditis | 1 | 2020 | 9 | 0.730 |
Why?
| Retinal Vein | 2 | 2019 | 3 | 0.690 |
Why?
| Eye Diseases | 3 | 2024 | 32 | 0.680 |
Why?
| Photography | 4 | 2013 | 32 | 0.680 |
Why?
| Eyeglasses | 1 | 2019 | 9 | 0.680 |
Why?
| Crohn Disease | 1 | 2020 | 90 | 0.670 |
Why?
| Surgical Instruments | 1 | 2019 | 27 | 0.670 |
Why?
| Trichoderma | 1 | 2019 | 1 | 0.670 |
Why?
| Plant Diseases | 1 | 2019 | 8 | 0.670 |
Why?
| Suture Techniques | 2 | 2022 | 57 | 0.650 |
Why?
| Laser Therapy | 1 | 2019 | 84 | 0.630 |
Why?
| Fovea Centralis | 1 | 2018 | 5 | 0.630 |
Why?
| Risk Factors | 11 | 2025 | 3604 | 0.630 |
Why?
| Basement Membrane | 1 | 2018 | 18 | 0.630 |
Why?
| Imaging, Three-Dimensional | 1 | 2019 | 152 | 0.620 |
Why?
| HIV Infections | 1 | 2022 | 355 | 0.620 |
Why?
| Vascular Endothelial Growth Factor A | 5 | 2022 | 183 | 0.610 |
Why?
| National Health Programs | 2 | 2015 | 18 | 0.610 |
Why?
| Fluocinolone Acetonide | 1 | 2017 | 5 | 0.590 |
Why?
| Egypt | 4 | 2022 | 13 | 0.590 |
Why?
| Vision Disorders | 5 | 2024 | 59 | 0.590 |
Why?
| Air | 2 | 2016 | 23 | 0.570 |
Why?
| Prospective Studies | 8 | 2024 | 2345 | 0.560 |
Why?
| Minerals | 1 | 2016 | 30 | 0.540 |
Why?
| Sodium Chloride | 1 | 2016 | 56 | 0.530 |
Why?
| Chorioretinitis | 3 | 2024 | 9 | 0.530 |
Why?
| Vitreous Detachment | 1 | 2016 | 1 | 0.530 |
Why?
| Acetates | 1 | 2016 | 49 | 0.530 |
Why?
| Ophthalmic Solutions | 2 | 2024 | 19 | 0.530 |
Why?
| Dissection | 1 | 2016 | 14 | 0.520 |
Why?
| Ophthalmologic Surgical Procedures | 1 | 2016 | 22 | 0.510 |
Why?
| Cross-Sectional Studies | 7 | 2024 | 1573 | 0.510 |
Why?
| Registries | 2 | 2018 | 522 | 0.510 |
Why?
| Anesthesia, Local | 1 | 2015 | 15 | 0.500 |
Why?
| Adrenergic alpha-1 Receptor Antagonists | 2 | 2020 | 8 | 0.490 |
Why?
| Child, Preschool | 10 | 2024 | 3875 | 0.490 |
Why?
| Patient Education as Topic | 4 | 2024 | 315 | 0.460 |
Why?
| Microvessels | 2 | 2024 | 29 | 0.460 |
Why?
| Device Removal | 1 | 2014 | 84 | 0.440 |
Why?
| Treponema pallidum | 3 | 2024 | 10 | 0.430 |
Why?
| Iris | 3 | 2022 | 6 | 0.420 |
Why?
| Vitreous Body | 5 | 2020 | 19 | 0.400 |
Why?
| Scleral Buckling | 3 | 2023 | 5 | 0.390 |
Why?
| Optic Disk | 2 | 2021 | 20 | 0.390 |
Why?
| Physical Examination | 2 | 2013 | 93 | 0.390 |
Why?
| Mydriatics | 1 | 2011 | 12 | 0.380 |
Why?
| Microscopy | 1 | 2011 | 58 | 0.370 |
Why?
| Seasons | 2 | 2022 | 81 | 0.360 |
Why?
| Diagnostic Techniques, Ophthalmological | 2 | 2023 | 11 | 0.340 |
Why?
| Anti-Bacterial Agents | 5 | 2024 | 742 | 0.340 |
Why?
| Genotype | 2 | 2023 | 538 | 0.340 |
Why?
| United States | 8 | 2024 | 4878 | 0.340 |
Why?
| Fibrinolytic Agents | 2 | 2023 | 125 | 0.330 |
Why?
| Intraoperative Period | 2 | 2019 | 45 | 0.330 |
Why?
| Vision, Low | 2 | 2022 | 9 | 0.330 |
Why?
| Fundus Oculi | 3 | 2024 | 25 | 0.330 |
Why?
| Lens Capsule, Crystalline | 2 | 2016 | 2 | 0.320 |
Why?
| Tonometry, Ocular | 2 | 2024 | 5 | 0.310 |
Why?
| Adrenergic alpha-Antagonists | 1 | 2008 | 27 | 0.310 |
Why?
| Silicone Oils | 3 | 2023 | 3 | 0.300 |
Why?
| Eye Infections, Viral | 1 | 2008 | 2 | 0.300 |
Why?
| Ocular Hypotension | 1 | 2008 | 2 | 0.300 |
Why?
| Eye Infections, Parasitic | 1 | 2008 | 2 | 0.300 |
Why?
| Choroid Neoplasms | 1 | 2007 | 6 | 0.300 |
Why?
| Suction | 1 | 2008 | 23 | 0.300 |
Why?
| Phenotype | 2 | 2022 | 728 | 0.290 |
Why?
| Physicians, Family | 1 | 2008 | 64 | 0.290 |
Why?
| Eye Burns | 1 | 2007 | 1 | 0.290 |
Why?
| Search Engine | 2 | 2024 | 10 | 0.280 |
Why?
| Consumer Health Information | 2 | 2024 | 18 | 0.280 |
Why?
| Sulfonamides | 1 | 2008 | 125 | 0.280 |
Why?
| Hyaluronic Acid | 1 | 2007 | 35 | 0.280 |
Why?
| Anti-Infective Agents | 1 | 2008 | 95 | 0.280 |
Why?
| Adolescent | 9 | 2024 | 6414 | 0.280 |
Why?
| Vaccination | 3 | 2024 | 275 | 0.260 |
Why?
| Young Adult | 8 | 2024 | 4029 | 0.250 |
Why?
| Muscarinic Agonists | 1 | 2024 | 11 | 0.240 |
Why?
| Administration, Topical | 1 | 2024 | 56 | 0.240 |
Why?
| Trabeculectomy | 1 | 2024 | 9 | 0.240 |
Why?
| Glaucoma Drainage Implants | 1 | 2024 | 6 | 0.240 |
Why?
| Cohort Studies | 2 | 2022 | 1403 | 0.240 |
Why?
| Limbus Corneae | 1 | 2024 | 8 | 0.240 |
Why?
| Vitreoretinopathy, Proliferative | 1 | 2024 | 3 | 0.230 |
Why?
| Syphilis Serodiagnosis | 1 | 2024 | 4 | 0.230 |
Why?
| Melanoma | 1 | 2007 | 281 | 0.230 |
Why?
| Garlic | 1 | 2024 | 5 | 0.230 |
Why?
| Proanthocyanidins | 1 | 2024 | 3 | 0.230 |
Why?
| Abducens Nerve Diseases | 1 | 2024 | 7 | 0.230 |
Why?
| Ciliary Arteries | 1 | 2024 | 3 | 0.230 |
Why?
| Burns, Chemical | 1 | 2024 | 9 | 0.230 |
Why?
| Propensity Score | 1 | 2024 | 125 | 0.230 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 488 | 0.230 |
Why?
| Pseudotumor Cerebri | 1 | 2024 | 26 | 0.230 |
Why?
| Glaucoma, Open-Angle | 1 | 2024 | 21 | 0.220 |
Why?
| Inflammation | 3 | 2022 | 603 | 0.220 |
Why?
| Tattooing | 1 | 2023 | 5 | 0.220 |
Why?
| Geographic Atrophy | 1 | 2023 | 2 | 0.220 |
Why?
| Sex Workers | 1 | 2023 | 2 | 0.220 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 122 | 0.220 |
Why?
| Drainage | 1 | 2023 | 79 | 0.220 |
Why?
| Cultural Diversity | 1 | 2023 | 38 | 0.220 |
Why?
| Fibrinolysin | 1 | 2023 | 2 | 0.220 |
Why?
| Dementia | 1 | 2024 | 113 | 0.220 |
Why?
| Self Report | 1 | 2024 | 202 | 0.220 |
Why?
| Odds Ratio | 1 | 2025 | 548 | 0.220 |
Why?
| Schools, Medical | 1 | 2023 | 70 | 0.210 |
Why?
| Retreatment | 2 | 2014 | 56 | 0.210 |
Why?
| ROC Curve | 1 | 2023 | 225 | 0.210 |
Why?
| Patient Selection | 1 | 2024 | 254 | 0.210 |
Why?
| Faculty, Medical | 1 | 2023 | 92 | 0.210 |
Why?
| Vision Screening | 1 | 2022 | 11 | 0.210 |
Why?
| Blood-Retinal Barrier | 1 | 2022 | 5 | 0.210 |
Why?
| Subretinal Fluid | 1 | 2022 | 2 | 0.210 |
Why?
| Disease Management | 2 | 2021 | 175 | 0.200 |
Why?
| Sudan | 1 | 2022 | 2 | 0.200 |
Why?
| Privacy | 1 | 2022 | 16 | 0.200 |
Why?
| Health Literacy | 4 | 2024 | 130 | 0.200 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2015 | 223 | 0.200 |
Why?
| Cyanoacrylates | 1 | 2021 | 6 | 0.200 |
Why?
| Fibrin Tissue Adhesive | 1 | 2021 | 12 | 0.200 |
Why?
| Recombinant Fusion Proteins | 1 | 2022 | 186 | 0.200 |
Why?
| Prednisone | 1 | 2022 | 100 | 0.200 |
Why?
| Eye Abnormalities | 1 | 2021 | 24 | 0.200 |
Why?
| Vision, Ocular | 1 | 2021 | 9 | 0.200 |
Why?
| Infant | 5 | 2024 | 3572 | 0.190 |
Why?
| Eye | 1 | 2021 | 24 | 0.190 |
Why?
| Ecosystem | 1 | 2022 | 64 | 0.190 |
Why?
| Prevalence | 3 | 2022 | 956 | 0.190 |
Why?
| Genome-Wide Association Study | 1 | 2022 | 163 | 0.190 |
Why?
| Sensitivity and Specificity | 1 | 2023 | 858 | 0.190 |
Why?
| Tomography, X-Ray Computed | 2 | 2022 | 1150 | 0.190 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2024 | 201 | 0.190 |
Why?
| Disease Outbreaks | 1 | 2022 | 123 | 0.190 |
Why?
| Prolapse | 1 | 2020 | 6 | 0.190 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2024 | 550 | 0.180 |
Why?
| Fungemia | 1 | 2021 | 37 | 0.180 |
Why?
| Electronic Health Records | 3 | 2018 | 209 | 0.180 |
Why?
| Swine | 1 | 2021 | 396 | 0.180 |
Why?
| Oximetry | 2 | 2011 | 65 | 0.180 |
Why?
| Ophthalmoscopy | 1 | 2020 | 14 | 0.180 |
Why?
| Macula Lutea | 1 | 2020 | 3 | 0.180 |
Why?
| Carcinoma, Hepatocellular | 1 | 2022 | 194 | 0.170 |
Why?
| Bacteria | 1 | 2022 | 219 | 0.170 |
Why?
| Retinal Pigment Epithelium | 1 | 2020 | 11 | 0.170 |
Why?
| Blindness | 2 | 2022 | 31 | 0.170 |
Why?
| Algorithms | 1 | 2023 | 613 | 0.170 |
Why?
| Substance Abuse, Intravenous | 1 | 2020 | 43 | 0.170 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2022 | 482 | 0.170 |
Why?
| Fusariosis | 1 | 2019 | 6 | 0.170 |
Why?
| Plant Roots | 1 | 2019 | 33 | 0.170 |
Why?
| Fusarium | 1 | 2019 | 31 | 0.160 |
Why?
| Referral and Consultation | 3 | 2013 | 284 | 0.160 |
Why?
| Quantitative Trait Loci | 1 | 2019 | 42 | 0.160 |
Why?
| Hepatitis C | 1 | 2020 | 80 | 0.160 |
Why?
| Liver Neoplasms | 1 | 2022 | 329 | 0.160 |
Why?
| MicroRNAs | 1 | 2022 | 347 | 0.160 |
Why?
| Animals | 3 | 2024 | 13100 | 0.160 |
Why?
| Emergencies | 2 | 2009 | 84 | 0.160 |
Why?
| Water | 1 | 2019 | 74 | 0.160 |
Why?
| Antibiotic Prophylaxis | 1 | 2019 | 61 | 0.160 |
Why?
| Chromosome Mapping | 1 | 2019 | 158 | 0.160 |
Why?
| Equipment Design | 1 | 2019 | 286 | 0.160 |
Why?
| Gaucher Disease | 1 | 2018 | 14 | 0.150 |
Why?
| Alleles | 1 | 2019 | 251 | 0.150 |
Why?
| Recurrence | 2 | 2011 | 658 | 0.150 |
Why?
| Surgical Wound Infection | 1 | 2019 | 114 | 0.150 |
Why?
| Sulfur Hexafluoride | 1 | 2017 | 2 | 0.150 |
Why?
| Treatment Failure | 1 | 2018 | 116 | 0.150 |
Why?
| Drug Therapy, Combination | 2 | 2016 | 380 | 0.150 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2024 | 483 | 0.150 |
Why?
| Eye Diseases, Hereditary | 1 | 2017 | 5 | 0.140 |
Why?
| Fatty Acids | 1 | 2018 | 143 | 0.140 |
Why?
| Inheritance Patterns | 1 | 2017 | 22 | 0.140 |
Why?
| Penicillins | 1 | 2017 | 28 | 0.140 |
Why?
| Contrast Media | 1 | 2018 | 186 | 0.140 |
Why?
| Time Factors | 3 | 2020 | 2891 | 0.140 |
Why?
| Video Recording | 1 | 2016 | 79 | 0.130 |
Why?
| Microsurgery | 2 | 2024 | 30 | 0.130 |
Why?
| Drug Combinations | 1 | 2016 | 126 | 0.130 |
Why?
| Anesthetics, General | 1 | 2015 | 4 | 0.130 |
Why?
| Visually Impaired Persons | 1 | 2015 | 1 | 0.120 |
Why?
| Dose-Response Relationship, Drug | 2 | 2016 | 1354 | 0.120 |
Why?
| England | 2 | 2012 | 45 | 0.120 |
Why?
| Anesthetics, Local | 1 | 2015 | 74 | 0.120 |
Why?
| Acute Disease | 2 | 2021 | 367 | 0.120 |
Why?
| Microscopy, Acoustic | 1 | 2013 | 5 | 0.110 |
Why?
| Language | 2 | 2024 | 134 | 0.110 |
Why?
| Diagnosis, Differential | 3 | 2017 | 1036 | 0.110 |
Why?
| Glaucoma, Neovascular | 1 | 2012 | 2 | 0.110 |
Why?
| Infusions, Intravenous | 2 | 2017 | 212 | 0.110 |
Why?
| Syndrome | 2 | 2011 | 237 | 0.090 |
Why?
| Risk Assessment | 1 | 2016 | 1254 | 0.090 |
Why?
| Mutation | 1 | 2017 | 1292 | 0.090 |
Why?
| Muscle Hypotonia | 1 | 2011 | 21 | 0.090 |
Why?
| Risperidone | 1 | 2011 | 25 | 0.090 |
Why?
| Eye Hemorrhage | 1 | 2010 | 1 | 0.090 |
Why?
| Cranial Sinuses | 1 | 2010 | 10 | 0.090 |
Why?
| Carotid Artery Injuries | 1 | 2010 | 13 | 0.090 |
Why?
| Arteriovenous Fistula | 1 | 2010 | 22 | 0.090 |
Why?
| Prostaglandins F, Synthetic | 1 | 2009 | 1 | 0.080 |
Why?
| Anti-Inflammatory Agents | 1 | 2011 | 160 | 0.080 |
Why?
| Prednisolone | 1 | 2009 | 55 | 0.080 |
Why?
| Carbonic Anhydrase Inhibitors | 1 | 2008 | 5 | 0.080 |
Why?
| Antipsychotic Agents | 1 | 2011 | 231 | 0.080 |
Why?
| Acetazolamide | 1 | 2008 | 18 | 0.080 |
Why?
| Oxygen | 1 | 2011 | 323 | 0.080 |
Why?
| Pupil | 1 | 2008 | 29 | 0.080 |
Why?
| Vitreous Hemorrhage | 1 | 2008 | 4 | 0.080 |
Why?
| Prostatic Hyperplasia | 1 | 2008 | 38 | 0.080 |
Why?
| Mass Screening | 1 | 2011 | 346 | 0.080 |
Why?
| Injections | 1 | 2008 | 56 | 0.080 |
Why?
| Electroretinography | 2 | 2018 | 17 | 0.070 |
Why?
| Models, Biological | 1 | 2011 | 719 | 0.070 |
Why?
| Cefuroxime | 1 | 2007 | 3 | 0.070 |
Why?
| Cefazolin | 1 | 2007 | 10 | 0.070 |
Why?
| Capsulorhexis | 1 | 2007 | 1 | 0.070 |
Why?
| Rupture | 1 | 2007 | 24 | 0.070 |
Why?
| Astigmatism | 1 | 2007 | 5 | 0.070 |
Why?
| Neoplasm Metastasis | 1 | 2007 | 235 | 0.070 |
Why?
| Chronic Disease | 1 | 2009 | 565 | 0.070 |
Why?
| Clinical Competence | 1 | 2008 | 395 | 0.060 |
Why?
| Reagins | 1 | 2024 | 2 | 0.060 |
Why?
| Posterior Eye Segment | 1 | 2024 | 2 | 0.060 |
Why?
| Sex Distribution | 1 | 2024 | 135 | 0.060 |
Why?
| Prosthesis Implantation | 1 | 2024 | 46 | 0.060 |
Why?
| Antibodies, Bacterial | 1 | 2024 | 27 | 0.060 |
Why?
| Rumen | 1 | 2024 | 1 | 0.060 |
Why?
| Tannins | 1 | 2024 | 3 | 0.060 |
Why?
| Fermentation | 1 | 2024 | 9 | 0.060 |
Why?
| Goats | 1 | 2024 | 11 | 0.060 |
Why?
| Diplopia | 1 | 2024 | 19 | 0.060 |
Why?
| Teaching Materials | 1 | 2024 | 30 | 0.060 |
Why?
| Animal Feed | 1 | 2024 | 55 | 0.060 |
Why?
| Reading | 1 | 2024 | 82 | 0.060 |
Why?
| Antifungal Agents | 1 | 2006 | 343 | 0.060 |
Why?
| Immunoglobulin G | 1 | 2024 | 184 | 0.050 |
Why?
| Anesthesia | 1 | 2024 | 73 | 0.050 |
Why?
| Surgical Flaps | 1 | 2024 | 114 | 0.050 |
Why?
| Homosexuality, Male | 1 | 2023 | 52 | 0.050 |
Why?
| Retinal Ganglion Cells | 1 | 2022 | 13 | 0.050 |
Why?
| Traction | 1 | 2021 | 7 | 0.050 |
Why?
| Reoperation | 2 | 2014 | 453 | 0.050 |
Why?
| Socioeconomic Factors | 1 | 2023 | 583 | 0.040 |
Why?
| Health Status Disparities | 1 | 2023 | 196 | 0.040 |
Why?
| Atrophy | 1 | 2020 | 38 | 0.040 |
Why?
| Diet | 1 | 2024 | 553 | 0.040 |
Why?
| Emergency Service, Hospital | 1 | 2024 | 487 | 0.040 |
Why?
| Healthcare Disparities | 1 | 2023 | 279 | 0.040 |
Why?
| Europe | 1 | 2019 | 75 | 0.040 |
Why?
| Pandemics | 1 | 2024 | 566 | 0.040 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2022 | 824 | 0.040 |
Why?
| Administration, Oral | 2 | 2011 | 433 | 0.040 |
Why?
| Glucosylceramidase | 1 | 2018 | 8 | 0.040 |
Why?
| Enzyme Replacement Therapy | 1 | 2018 | 17 | 0.040 |
Why?
| Visual Fields | 1 | 2018 | 36 | 0.040 |
Why?
| Transplantation, Autologous | 1 | 2020 | 462 | 0.040 |
Why?
| Prone Position | 1 | 2017 | 31 | 0.040 |
Why?
| Genes, Recessive | 1 | 2017 | 16 | 0.040 |
Why?
| Consanguinity | 1 | 2017 | 18 | 0.040 |
Why?
| Heterozygote | 1 | 2017 | 81 | 0.040 |
Why?
| Pedigree | 1 | 2017 | 125 | 0.040 |
Why?
| Recombinant Proteins | 1 | 2018 | 482 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2017 | 176 | 0.030 |
Why?
| Genetic Association Studies | 1 | 2017 | 115 | 0.030 |
Why?
| Genetic Testing | 1 | 2017 | 119 | 0.030 |
Why?
| Rupture, Spontaneous | 1 | 2016 | 19 | 0.030 |
Why?
| Practice Guidelines as Topic | 1 | 2019 | 458 | 0.030 |
Why?
| Pregnancy | 1 | 2023 | 2468 | 0.030 |
Why?
| Survival Analysis | 1 | 2016 | 670 | 0.030 |
Why?
| Choroidal Neovascularization | 1 | 2013 | 19 | 0.030 |
Why?
| Gonioscopy | 1 | 2012 | 3 | 0.030 |
Why?
| Age Distribution | 1 | 2013 | 169 | 0.030 |
Why?
| Neovascularization, Pathologic | 1 | 2012 | 153 | 0.020 |
Why?
| Retinal Artery | 1 | 2011 | 5 | 0.020 |
Why?
| Coloring Agents | 1 | 2011 | 67 | 0.020 |
Why?
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2011 | 9 | 0.020 |
Why?
| Indocyanine Green | 1 | 2011 | 34 | 0.020 |
Why?
| Dopamine Antagonists | 1 | 2011 | 21 | 0.020 |
Why?
| Angiography | 1 | 2011 | 127 | 0.020 |
Why?
| Injections, Intraocular | 1 | 2010 | 2 | 0.020 |
Why?
| Regional Blood Flow | 1 | 2011 | 106 | 0.020 |
Why?
| Methylprednisolone | 1 | 2010 | 38 | 0.020 |
Why?
| Orbit | 1 | 2010 | 27 | 0.020 |
Why?
| Chemotherapy, Adjuvant | 1 | 2011 | 121 | 0.020 |
Why?
| Adrenal Cortex Hormones | 1 | 2011 | 99 | 0.020 |
Why?
| Schizophrenia | 1 | 2011 | 257 | 0.020 |
Why?
| Immunosuppressive Agents | 1 | 2011 | 226 | 0.020 |
Why?
| Sweden | 1 | 2007 | 10 | 0.020 |
Why?
|
|
Sallam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|